SB010 / Sterna Biologicals - LARVOL DELTA

Sterna biologicals announces dosing of first patient in phase IIA proof-of-concept study with SB010 in moderate to severe asthma - '"Today, the standard of care treatment regimen for moderate to severe Type 2-driven asthma is not sufficient for a large number of patients, who continue to experience asthma symptoms and exacerbations and, over time, disease worsening,' said Prof. Dr. med. Tobias Welte..."

Media quote

Sterna Biologicals Announces Dosing of First Patient in Phase IIa Proof-of-concept Study with SB010 in Moderate to Severe Asthma (BioSpace) - "sterna biologicals GmbH & Co. KG...today announced that the first patient has been dosed in the Company's phase IIa proof-of-concept (POC) trial with SB010 in patients with moderate to severe Type-2 driven asthma....The primary objective is to evaluate the effect on airway inflammation as measured by the change in the fraction of exhaled nitric oxide (FeNO)....The study is planned to enroll approximately 100 patients at 18 centers in Germany....Results from the trial are expected in late 2022/early 2023."

P2a data • Trial status • Asthma • Respiratory Diseases

Biological Impact and Enzyme Activities of Spodoptera litura (Lepidoptera: Noctuidae) in Response to Synergistic Action of Matrine and Beauveria brongniartii. (PubMed, Front Physiol) - "Following on, we measured the activities of five important antioxidant enzymes [superoxide dismutase (SOD), peroxidase (POD), catalase (CAT), acetylcholinesterase (AChE), and glutathione-S-transferase (GST)] when treated with B. brongniartii SB010 (1 × 10 spores/ml), matrine (0.5 mg/ml), and B. brongniartii SB010 (1 × 10 spores/ml) + matrine (0.5 mg/ml)...Matrine had better inhibition effects than B. brongniartii in a majority of the trials. The improved detoxification activity of the five enzymes may be the internal mechanism of synergism of matrine on B. brongniartii."

Journal • Pain • CAT

A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial. (PubMed, Respir Res) - "In patients with eosinophilic COPD, sputum eosinophils could be reduced by inhalation of SB010. Long-term studies are needed to demonstrate clinical efficacy."

Biomarker • Clinical • Journal • Asthma • Biosimilar • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps. (PubMed, Am J Rhinol Allergy) - "These treatments have promising results and may prove to be an important adjunct for patients with recalcitrant sinus disease."

Journal